The acquisition of XOMA is expected to be immediately accretive to Ligand's earnings and significantly expand its royalty portfolio. Traders should monitor the progress of shareholder and regulatory approvals, as well as the outcome of XOMA's litigation with Janssen Biotech, which could impact the value of the CVRs.
Price Chart
Executive Summary
Ligand Pharmaceuticals (LGND) is acquiring XOMA Royalty Corporation (XOMA) in an all-cash transaction valued at approximately $739 million, plus contingent value rights (CVRs). XOMA shareholders will receive $39.00 per share in cash and one non-transferable CVR per share, which entitles them to a portion of potential net proceeds from XOMA's ongoing litigation with Janssen Biotech. The deal is expected to close in Q3 2026, pending shareholder and regulatory approval.
Key Financial Metrics
Key Facts
- Ligand is acquiring XOMA Royalty Corporation for $39.00 per share in cash.
- The total equity value of the transaction is approximately $739 million.
- XOMA shareholders will also receive one non-transferable contingent value right (CVR) per share.
- The CVRs entitle holders to a portion of 75% of the net proceeds from XOMA's litigation with Janssen Biotech.
- The transaction is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
- The acquisition is expected to be immediately accretive to Ligand's adjusted EPS, adding $0.50 in 2026 and $1.50 in 2027.
- The deal will double the size of Ligand's royalty portfolio, adding seven new commercial products and over 100 development-stage programs.
Financial Impact
The transaction has an equity value of approximately $739 million. The acquisition is expected to be immediately accretive to Ligand's adjusted EPS, adding $0.50 in 2026 and $1.50 in 2027.
Risk Factors
- The transaction is subject to customary closing conditions, including shareholder and regulatory approvals, which may not be obtained in a timely manner or at all.
- The value of the CVRs is contingent on the outcome of XOMA's litigation with Janssen Biotech, which is uncertain.
- The integration of XOMA's business into Ligand may not be successful, which could impact the expected benefits of the acquisition.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-179529 |
| Document: d143046d8k.htm | 0001193125-26-179529 |
| Document: d143046dex101.htm | 0001193125-26-179529 |
| Document: d143046dex992.htm | 0001193125-26-179529 |
| Document: d143046dex991.htm | 0001193125-26-179529 |
| Document: 0001193125-26-179529-index-headers.html | 0001193125-26-179529 |
| Document: 0001193125-26-179529-index.html | 0001193125-26-179529 |
| Document: 0001193125-26-179529.txt | 0001193125-26-179529 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 18, 2026 23w ago | DEFA14A | — | awaiting T+5 | — | — |
May 18, 2026 23w ago | 8-K | — | awaiting T+5 | — | — |
Apr 30, 2026 25w ago | 8-K | — | awaiting T+5 | — | — |
Apr 27, 2026 26w ago | DEFA14A | $0.0400 $0.0500 | ▲ +25.00% | ▲ +24.32% | — |
Apr 27, 2026 26w ago | 8-K | $0.0400 $0.0500 | ▲ +25.00% | ▲ +24.32% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers